For the subset of patients with ST-elevation myocardial infarction, P2Y12 inhibitors were used less appropriately under the new vs. previous guidelines (31.4 vs. 55.0%, p < .001). Here, P2RY12 is linked to ST Elevation Myocardial Infarction.